New York University - College of Dentistry
Home The College Research Academic Programs Library/Resources Continuing Education Community Outreach International Programs
Click to View Virtual Tour

 > News


NYU College of Dentistry Participates in Federally-Funded Breast Cancer Research Project

Dr. Joseph B. Guttenplan
$680,000 Award to Study How Estrogen Reacts With DNA The NYU College of Dentistry (NYUCD) has received a four-year, $680,000 grant for research that could pave the way for the development of new approaches to breast cancer prevention. The grant’s principal investigator, NYUCD Professor of Basic Science and Craniofacial Biology Dr. Joseph B. Guttenplan, will evaluate how estrogen metabolites react with DNA to create mutations leading to breast cancer. His research is part of a larger breast cancer prevention and treatment study involving several other institutions cooperating in a Center Grant consortium under the auspices of the U.S. Department of Defense.

Dr. Guttenplan’s laboratory is one of only a handful in the U.S. that can analyze and measure mutations in rat and mouse organs. Dr. Guttenplan is using the same mutation analysis model in oral cancer research studies. “Estrogens are known to increase the cell division rate in estrogen-sensitive cells, such as breast cells. However, if estrogens also cause mutations, the chance that the cellular reproduction leads to cancer would be greatly increased,” Dr. Guttenplan said. “My research, which is being conducted in cooperation with investigators at the University of Nebraska Medical School, examines the process by which estrogen metabolites damage DNA and perhaps trigger breast cancer in rats. “I will also look at the role that two substances may play in inhibiting estrogen-induced mutations. One of these substances -- 1, 2-dithiole-3-thione -- is found in cruciferous vegetables, such as cauliflower and broccoli. The other substance, N-acetycysteine has been used in Europe for many years to treat cold symptoms and has antioxidant and other chemical properties that indicate that it may play a role in cancer prevention. Results of these analyses could be used to incorporate the substances into the development of a drug or dietary supplement for breast cancer prevention.” In another arm of the study, researchers will examine questions left unanswered by recent trials that found that new drug regimens can markedly reduce the chance that breast cancer will recur in postmenopausal women whose cancer was fueled by estrogen. Those women had stopped taking the drug tamoxifen, which blocks estrogen, because tamoxifen’s effectiveness diminishes after five years, or took another class of drugs (aromatase inhibitors) instead.

The study found that members of this latter class of drugs, such as letrozole, can cut the yearly risk of cancer recurrence in half. In one case, the results were so strongly, and surprisingly, positive that the investigators ended the study early and offered the drug to women taking a placebo. However, questions remain, including how long women should take letrozole and at what doses. In addition, the important details in the mechanism by which drugs such as letrozole act have not been established. If these details are known, it may be possible to design even more effective treatments and/or better use for the current drugs. The results of research conducted by Dr. Guttenplan and his colleagues will be combined with the letrozole study results and with findings from another study on the prevention of mutations in cultured human breast cells. It is hoped that the combined results will ultimately be used to design and prepare a breast cancer prevention trial in women. Other institutions participating in the research consortium include the Fox-Chase Cancer Center in Philadelphia, the Mayo Clinic in Rochester, Minnesota, the University of Virginia Health System in Charlottesville, and the University of Memphis in Tennessee. This article originally appeared in the Winter 2004 issue of Global Health Nexus, the magazine of NYU College of Dentistry.

View All News Archive Media Contacts
Share on Facebook